™Cancer prevalence is not trial participation
The 19.5% and 9.0% figures describe the share of respondents reporting that they had ever been diagnosed with cancer. They do not measure annual cancer incidence, an individual's future risk, or enrollment in research. Age and other population differences matter when interpreting a comparison between veterans and nonveterans.
The finding nonetheless makes the burden visible and gives canXcer a reason to ask whether research questions, datasets, and access routes adequately represent veterans.
The separate prostate-cancer trial-access measure
A March 2024 review of 1,884 phase 2–3 prostate-cancer trials registered after January 1, 2007 found that 6% included at least one VA site. In March 2024, 38% of 159 VA facilities had an active phase 2–3 trial. These historical percentages describe trial availability at VA sites, not how many veterans enrolled or were excluded, and they do not establish current availability.
Keeping the two studies and their denominators visible helps readers understand both the burden and one access barrier without implying that one statistic caused the other.
What canXcer can contribute
canXcer makes representation and evidence gaps visible when researchers frame questions and compare cohorts. A separate veteran research path supports participant-controlled service information without inferring exposure or causation from service locations. Software cannot by itself solve trial access, replace VA or community programs, or determine care for an individual veteran.